Related references
Note: Only part of the references are listed.Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection
Michael Kozal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529
Ishani Landry et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Pharmacokinetic Interactions between BMS-626529, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug BMS-663068, and Ritonavir or Ritonavir-Boosted Atazanavir in Healthy Subjects
Li Zhu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial
Jacob P. Lalezari et al.
LANCET HIV (2015)
Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action
David R. Langley et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2015)
Efficacy of Initial Antiretroviral Therapy for HIV-1 Infection in Adults: A Systematic Review and Meta-Analysis of 114 Studies with up to 144 Weeks' Follow-Up
Frederick J. Lee et al.
PLOS ONE (2014)
Compartmental absorption modeling and site of absorption studies to determine feasibility of an extended-release formulation of an HIV-1 attachment inhibitor phosphate ester prodrug
Jonathan Brown et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe
Fumiyo Nakagawa et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2012)
Pharmacokinetic Interactions of Maraviroc with Darunavir-Ritonavir, Etravirine, and Etravirine-Darunavir-Ritonavir in Healthy Volunteers: Results of Two Drug Interaction Trials
Thomas N. Kakuda et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years
ARCHIVES OF INTERNAL MEDICINE (2010)
Share Paper
